This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the potential of Takeda's enzyme replacement therapy, TAK-755 in treating congenital thrombotic thrombocytopenic purpura (cTTP)

Ticker(s): TAK

Who's the expert?

Institution: Case Western

  • Professor of Hematology and Oncology in Medicine and Pathology at Case Western Reserve University and University Hospitals Cleveland Medical Center (previously Professor at Temple and Univ. of Michigan)
  • Manages 5 patients with cTTP; practice that is exclusively hemostasis, thrombosis, and hemophilia.
  • Research has focused on the vascular biology of factor XII and the kallikrein/kinin system and hemostasis and thrombosis. 

Interview Goal
This conversation will focus on the standard of care for cTTP and the recent interim analysis of Takeda’s ERT, dubbed TAK-755.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.